Váradi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz H P
Research Laboratories of Immuno AG, Vienna, Austria.
Thromb Haemost. 1996 Aug;76(2):208-14.
Factor V and protein S are cofactors of activated protein C (APC) which accelerate APC-mediated factor VIII inactivation. The effects of factor V and protein S were quantitated in a reaction system in which plasma factor VIII was inactivated by APC and the loss of factor VIII activity was monitored in a factor X-activating system in which a chromogenic substrate was used to probe factor Xa formation. Factor V increased the rate of APC-mediated factor VIII inactivation in a dose-dependent manner in representative plasma samples with protein S or factor V deficiency, abnormal factor V (heterozygous or homozygous for factor VR506Q), or a combination of heterozygous protein S deficiency and heterozygous factor VR506Q. This effect was much less pronounced in the plasma samples with a decreased protein S level, but the impaired response in these plasmas was corrected by addition of protein S, indicating that both factor V and protein S are required for optimal inactivation of factor VIII by APC. The effects of factor V and protein S were also studied in a reaction system with purified proteins. APC-catalysed factor VIII inactivation was enhanced 3.7-fold in the presence of 1.1 nM factor V and 1.5-fold in the presence of 2.4 nM protein S. When both 1.1 nM factor V and 2.4 nM protein were present the rate enhancement was 11-fold. Factor V is a more potent cofactor than protein S, as can be concluded from the fact that 0.04 nM factor V gave the same stimulation as 2.4 nM protein S. Protein S lost its cofactor function after complexation with C4b binding protein, which indicates that it is free protein S that acts as a cofactor. To investigate the effect of the R506Q mutation in factor V on APC-mediated factor VIII inactivation, factor V was purified from the plasma of patients homozygous for factor VR506Q. In the absence of protein S, factor VR506Q did not enhance factor VIII inactivation by APC, but in the presence of 2.4 nM protein S a slight enhancement was observed. The APC cofactor activity of factor V was lost when factor V was activated with thrombin or with the factor V activator from Russell's viper venom. These data indicate that optimal inactivation of factor VIII by APC requires the presence of an intact factor V molecule and free protein S.
因子V和蛋白S是活化蛋白C(APC)的辅因子,可加速APC介导的因子VIII失活。在一个反应系统中对因子V和蛋白S的作用进行了定量分析,在该系统中,血浆因子VIII被APC失活,并在一个因子X激活系统中监测因子VIII活性的丧失,在该系统中使用发色底物来检测因子Xa的形成。在具有蛋白S或因子V缺乏、异常因子V(因子VR506Q杂合或纯合),或杂合蛋白S缺乏与杂合因子VR506Q组合的代表性血浆样本中,因子V以剂量依赖的方式增加了APC介导的因子VIII失活速率。在蛋白S水平降低的血浆样本中,这种作用不太明显,但通过添加蛋白S可纠正这些血浆中受损的反应,这表明因子V和蛋白S都是APC使因子VIII最佳失活所必需的。还在一个含有纯化蛋白的反应系统中研究了因子V和蛋白S的作用。在存在1.1 nM因子V的情况下,APC催化的因子VIII失活增强了3.7倍,在存在2.4 nM蛋白S的情况下增强了1.5倍。当同时存在1.1 nM因子V和2.4 nM蛋白S时,速率增强了11倍。因子V是比蛋白S更有效的辅因子,从0.04 nM因子V与2.4 nM蛋白S产生相同刺激这一事实可以得出此结论。蛋白S与C4b结合蛋白结合后失去其辅因子功能,这表明起辅因子作用的是游离蛋白S。为了研究因子V中的R506Q突变对APC介导的因子VIII失活的影响,从因子VR506Q纯合患者的血浆中纯化了因子V。在没有蛋白S的情况下,因子VR506Q不会增强APC对因子VIII的失活作用,但在存在2.4 nM蛋白S的情况下观察到轻微增强。当因子V用凝血酶或来自锯鳞蝰蛇毒的因子V激活剂激活时,因子V的APC辅因子活性丧失。这些数据表明,APC使因子VIII最佳失活需要完整的因子V分子和游离蛋白S的存在。